BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Kaken Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Kaken Pharmaceutical's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05739435-1803@assetmemo.bio
DTSTAMP:20261121T010137Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Envudeucitinib: Phase 2 readout est. (NCT05739435)
DESCRIPTION:Envudeucitinib\, phase 2\, Psoriasis.\nStudy: Open-Label Extens
 ion Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaq
 ue Psoriasis\nEstimated primary completion: 1 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/envudeucitinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05739435
URL:https://assetmemo.bio/drug/envudeucitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03301506-1117@assetmemo.bio
DTSTAMP:20261121T010137Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Livdelzi (Seladelpar): Phase 3 readout est. (NCT03301506)
DESCRIPTION:Livdelzi (Seladelpar)\, phase 3\, Primary Biliary Cholangitis.\
 nStudy: Study of Seladelpar in Participants With Primary Biliary Cholangit
 is (PBC)\nEstimated primary completion: November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/seladelpar#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03301506
URL:https://assetmemo.bio/drug/seladelpar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846541-1803@assetmemo.bio
DTSTAMP:20261121T010137Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Envudeucitinib: Phase 3 readout est. (NCT06846541)
DESCRIPTION:Envudeucitinib\, phase 3\, Psoriasis.\nStudy: Long-term Safety 
 and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis\nEstimated 
 primary completion: November 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/envudeucitinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06846541
URL:https://assetmemo.bio/drug/envudeucitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841977-1117@assetmemo.bio
DTSTAMP:20261121T010137Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Livdelzi (Seladelpar): Phase 2 readout est. (NCT07841977)
DESCRIPTION:Livdelzi (Seladelpar)\, phase 2\, Primary Biliary Cholangitis.\
 nStudy: Study of Seladelpar and Cilofexor in Participants With Primary Bil
 iary Cholangitis\nEstimated primary completion: December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/seladelpar#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07841977
URL:https://assetmemo.bio/drug/seladelpar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06051617-1117@assetmemo.bio
DTSTAMP:20261121T010137Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Livdelzi (Seladelpar): Phase 3 readout est. (NCT06051617)
DESCRIPTION:Livdelzi (Seladelpar)\, phase 3\, Primary Biliary Cholangitis.\
 nStudy: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and 
 Compensated Cirrhosis\nEstimated primary completion: August 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/seladelpar#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06051617
URL:https://assetmemo.bio/drug/seladelpar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
